Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Standard Biotools (LAB) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Standard Biotools (LAB) over the last 17 years, with Q3 2025 value amounting to $382.6 million.

  • Standard Biotools' Shares Outstanding (Weighted Average) rose 298.54% to $382.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $382.6 million, marking a year-over-year increase of 298.54%. This contributed to the annual value of $353.2 million for FY2024, which is 34624.18% up from last year.
  • Standard Biotools' Shares Outstanding (Weighted Average) amounted to $382.6 million in Q3 2025, which was up 298.54% from $380.5 million recorded in Q2 2025.
  • Standard Biotools' 5-year Shares Outstanding (Weighted Average) high stood at $382.6 million for Q3 2025, and its period low was $74.7 million during Q1 2021.
  • Over the past 5 years, Standard Biotools' median Shares Outstanding (Weighted Average) value was $79.1 million (recorded in 2023), while the average stood at $182.3 million.
  • In the last 5 years, Standard Biotools' Shares Outstanding (Weighted Average) soared by 32.32% in 2023 and then soared by 37206.4% in 2024.
  • Quarter analysis of 5 years shows Standard Biotools' Shares Outstanding (Weighted Average) stood at $75.8 million in 2021, then grew by 3.32% to $78.3 million in 2022, then increased by 1.09% to $79.2 million in 2023, then soared by 346.24% to $353.2 million in 2024, then increased by 8.32% to $382.6 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $382.6 million for Q3 2025, versus $380.5 million for Q2 2025 and $378.2 million for Q1 2025.